IMR Press / EJGO / Volume 25 / Issue 3 / pii/2004180

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Human chorionic gonadotropin­beta in endometrium cancer tissue

Show Less
1 Division of Obstetrics and Gynecology, Department of Gynecologic Oncology, Karol Marcinkowski University of Medical Science, Poznan (Poland)
2 Department of Radiobiology and Cell Biology, Karol Marcinkowski University of Medical Science, Poznan (Poland)
Eur. J. Gynaecol. Oncol. 2004, 25(3), 351–354;
Published: 10 June 2004

Purpose: Determination of the correlation between expression of human chorionic gonadotropin mRNA and serum free hCGb immunoreactivity in endometrial cancer tissue. Methods: The study included 56 patients with endometrial carcinoma Stages IB-Ill. The expression of mRNA hCGβ was deter­minated by the RT PCR method in 18 cases of cancerous and precancerous tissues. The serum-free hCGβ immunoreactivity was analyzed by sequential immunometric assay in all patients. Results: In 15 study specimens of endometrial carcinoma tissue mRNA of hCGβ was detected. Also in endometrial atypical hyper­plasia, expression of hCGβ was found. Noncancerous tissue demonstrated lack of the hCGβ transcript. The serum immunoreactiv­ity in the endometrial cancer group was detectable in 86% of cases. There were no significant differences between FIGO stages and grading. Conclusion: The results of the present study confirmed the presence of active genes of hCGβ in endometrial cancer tissue, even in precancerous changes. The serum immunoreactivity of free hCGβ is a less common feature and is not linked with tumor stage or grade in endometrial cancer patients.

Human chorionic gonadotropin beta
mRNA of hCGβ
Endometrial carcinoma.
Back to top